Home Ingredients Magnesium Orotate
Cardiovascular

Magnesium Orotate

Evidence Level
Limited
2 Clinical Trials
5 Documented Benefits
2/5 Evidence Score

Magnesium orotate is the magnesium salt of orotic acid, supplying only about 6-7% elemental magnesium by weight. It is most often marketed for cardiovascular and exercise applications, with the orotate carrier promoted as helping shuttle magnesium into heart and muscle cells. The most cited form-specific human data is a single small double-blind trial in 79 patients with severe (NYHA class IV) congestive heart failure, run at a single centre, published as a letter and never independently repeated. The only trial in healthy people, 23 triathletes, reported faster swim, cycle and run times in the supplemented group but the authors concluded the supplement did not affect competitive potential. At about 6.5 percent elemental magnesium a 500 mg capsule supplies roughly 33 mg of magnesium, against an adult RDA of 310 to 420 mg, so a typical bottle delivers neither a meaningful magnesium dose nor the gram amounts used in the cardiac research. The rest of the compound is orotic acid, and in 2025 EFSA concluded that the safety of magnesium orotate dihydrate in food supplements cannot be established, because orotic acid has tumour-promoting effects in animal studies and the proposed supplement intake leaves no margin below the level judged safe in animals.

Studied Dose 6,000 mg/day for 1 month then 3,000 mg/day in the severe heart failure trial; 3,000 mg/day in the coronary heart disease pilot; 17 mmol/day (about 6,300 mg) for 4 weeks in the triathlete trial.
Active Compound Magnesium orotate dihydrate (C10H6MgN4O8 x 2H2O, molecular weight 370.5), the Mg(2+) salt of orotic acid: about 6.5 percent elemental magnesium by weight and about 84 percent orotate.

Benefits

Studied in diagnosed heart patients, not in healthy hearts

One randomized double-blind trial gave magnesium orotate to 79 patients with severe congestive heart failure who were already on full cardiac medication and reported higher one-year survival and better symptoms than placebo. It was a single-centre study, published as a short letter, and no independent group has repeated it. Two other small studies, 14 patients with coronary heart disease and 32 patients after bypass surgery in a single-blind study, reported better exercise capacity. All of this is research in diagnosed cardiac patients under medical care. It does not show that magnesium orotate protects a healthy heart, and magnesium orotate is not a treatment for any heart condition.

Supported by Trial 1

How much magnesium a capsule actually delivers

Magnesium orotate is about 6.5 percent elemental magnesium, so a 500 mg capsule supplies roughly 33 mg. Adult magnesium RDAs are 310 to 320 mg for women and 400 to 420 mg for men, so one 500 mg capsule covers under 10 percent of a day's magnesium. Reaching 100 to 200 mg of elemental magnesium takes 1,500 to 3,000 mg of the salt, which also brings 1,300 to 2,500 mg of orotic acid with it. EFSA did not carry out the comparison of magnesium absorption from this salt against natural sources, so claims that it is better absorbed than cheaper forms are not established.

Supported by Trial 1, Trial 2

Energy metabolism: a general magnesium role, not an orotate finding

Magnesium is required for ATP to be biologically active, and magnesium as a nutrient carries authorised claims for normal energy-yielding metabolism and for reducing tiredness. That is a property of the mineral, not of the orotate salt: no published trial of magnesium orotate has reported a fatigue or energy outcome. A 500 mg capsule also supplies only about 33 mg of magnesium, which is 9 percent of the 375 mg EU reference intake and below the 15 percent needed before a magnesium claim can be made at all.

Supported by Trial 1

Muscle and nerve function: not demonstrated for this salt

Magnesium helps regulate muscle contraction and nerve signalling, and that is true of any magnesium salt. The one trial in healthy athletes, 23 competitive triathletes given magnesium orotate for 4 weeks, reported lower cortisol and a smaller rise in creatine kinase after a triathlon, and faster swim, cycle and run times, but the authors concluded that the supplement did not affect competitive potential. No trial of magnesium orotate has measured muscle strength, soreness or cramp.

Supported by Trial 1, Trial 2

The orotate carrier claim is unproven

Orotic acid is an intermediate in the body's pyrimidine nucleotide pathway. Sellers describe it as a carrier that shuttles magnesium into heart and muscle cells; no human study has shown that magnesium orotate raises tissue magnesium more than a cheaper salt does. Orotic acid is also the part of the molecule regulators are concerned about, because animal studies show it has tumour-promoting effects, chiefly in rat liver.

Supported by Trial 1, Trial 2

Mechanism of action

1

Magnesium repletion

Dissociated magnesium ions are absorbed in the intestine and distributed to bone, muscle and soft tissue, restoring a cofactor essential for ATP utilization, DNA and protein synthesis, and ion transport across cell membranes.

2

Cardiac electrophysiology

Magnesium modulates calcium and potassium handling in cardiac and vascular smooth muscle cells, helping stabilize membrane excitability and supporting normal heart rhythm and vascular tone when magnesium status is adequate.

3

Orotate in nucleotide synthesis

Orotic acid is a precursor in pyrimidine nucleotide biosynthesis. Proponents propose this may aid cellular energy substrate and nucleic acid pools in metabolically active tissue, though a unique clinical effect of the orotate moiety is unconfirmed.

4

Calcium channel modulation

Acting as a natural calcium antagonist at the cellular level, magnesium influences smooth muscle relaxation and helps counterbalance calcium-driven contraction in blood vessels.

Clinical trials

1
MACH: one small unreplicated trial in severe congestive heart failure
PubMed

Monocentric double-blind randomized placebo-controlled trial over about one year, published as a letter in the International Journal of Cardiology and corrected and republished there

79 patients with severe (NYHA class IV) congestive heart failure at a single centre in Russia, all on optimal cardiovascular medication: 40 received magnesium orotate 6,000 mg/day for 1 month then 3,000 mg/day for about 11 months, 39 received placebo

Reported one-year survival was 75.7 percent with magnesium orotate versus 51.6 percent with placebo (p less than 0.05), and symptoms improved in 38.5 percent on magnesium orotate while worsening in 56.3 percent on placebo (p less than 0.001). This is one small single-centre study in severely ill cardiac patients who were already on full medical therapy, and no independent group has repeated it. It says nothing about people without heart failure, and magnesium orotate is not a treatment for heart failure.

2
Magnesium orotate and exercise tolerance in 14 coronary heart disease patients
PubMed

Double-blind placebo-controlled pilot study over 4 weeks, magnesium orotate 3 x 1 g per day added to existing medication

14 patients with coronary heart disease and left ventricular dysfunction attending an outpatient cardiac exercise group

Exercise duration on ergometry rose significantly (p = 0.011) and left ventricular end-systolic volume fell (p = 0.016) over 4 weeks. With 14 patients, no follow-up study and a cardiac-rehabilitation population, this is a preliminary signal in diagnosed patients, not evidence for healthy people or for sports performance.

Side effects and drug interactions

Common Potential side effects

Loose stools or diarrhea can occur, especially at higher doses, as with most magnesium salts.
Mild stomach upset, nausea or abdominal cramping is possible in sensitive individuals.
Low elemental magnesium content (about 33 mg per 500 mg capsule) means many capsules are needed to reach a useful magnesium dose, which raises both GI exposure and orotic acid intake. The upper limit for supplemental magnesium is 250 mg/day in the EU and 350 mg/day in the US, on top of food.
People with kidney impairment can accumulate magnesium and should consult a clinician first.
Orotic acid, about 84 percent of the compound by weight, is the main safety question. In 2025 EFSA concluded that the safety of magnesium orotate dihydrate as a food supplement ingredient cannot be established: animal studies show orotic acid has tumour-promoting effects, the no-observed-adverse-effect level derived for orotic acid is 50 mg/kg body weight per day (about 3,500 mg/day for a 70 kg adult), and the proposed maximum use level of 6,100 mg/day of the salt supplies roughly 5,000 mg of orotic acid, leaving a margin of 0.7. That application was made because magnesium orotate dihydrate is not among the magnesium sources currently permitted in EU food supplements, and EFSA did not clear it.

Important Drug interactions

May reduce absorption of oral tetracycline and quinolone antibiotics; separate dosing by 2-4 hours.
Can decrease absorption of oral bisphosphonates used for bone health; take several hours apart.
Magnesium may add to the effects of blood-pressure-lowering and antiarrhythmic medications.
Potassium-sparing diuretics and impaired kidney function raise the risk of magnesium accumulation.

More Cardiovascular Ingredients

Cardiovascular
Omega-3 Fatty Acids
Omega-3 fatty acids are polyunsaturated fats. EPA and DHA come from fish, krill and algae…
Cardiovascular
CoEnzyme Q10
Coenzyme Q10 (CoQ10) is a fat-soluble compound the body makes for itself. It carries elect…
Cardiovascular
Beetroot
Beetroot is a vegetable rich in dietary nitrate, which the body converts into nitric oxide…
Cardiovascular
Potassium
Potassium is the main mineral inside the body's cells and an essential nutrient for the el…

Explore Other Ingredients

Cognitive
Ashwagandha
Ashwagandha (Withania somnifera) is an herb from Ayurvedic tradition whose root extracts a…
Cognitive
KSM-66®
KSM-66 is a widely studied branded ashwagandha (Withania somnifera) extract, made by Ixore…
Cognitive
Rhodiola Rosea
Rhodiola rosea is an adaptogenic herb traditionally used in cold northern regions to comba…

Related articles from our blog

📝 Article
Magnesium and Heart Palpitations: What the Evidence Shows
A fluttering, pounding or skipping heartbeat is unsettling, and magnesium is the supplement people reach for first. The…
October 5, 2026

Frequently asked questions about Magnesium Orotate

What is magnesium orotate?

Magnesium orotate is magnesium bound to orotic acid, and it is only about 6.5 percent magnesium by weight. In Germany it is sold as a non-prescription pharmacy medicine (Magnerot) licensed for magnesium deficiency, and in the United States as a dietary supplement. It has been studied in cardiac patients and in triathletes, but its absorption has not been shown to beat cheaper magnesium salts, and it is one of the more expensive forms.

What is magnesium orotate used for?

It is marketed for the heart and for exercise. The research behind that is one small trial in patients with severe heart failure, two small studies in coronary and post-bypass patients, and one trial in 23 triathletes whose authors concluded the supplement did not affect competitive potential. The idea that orotic acid feeds energy production in heart and muscle cells comes from rat and cell work, not from measurements in people taking it.

How much magnesium orotate should I take?

Read the elemental magnesium figure, not the total. At about 6.5 percent magnesium, a 500 mg capsule gives roughly 33 mg, so 100 to 200 mg of elemental magnesium takes 1,500 to 3,000 mg of the salt and brings 1,300 to 2,500 mg of orotic acid with it. Given the EFSA finding on orotic acid and the price, a cheaper magnesium salt is the simpler way to raise magnesium intake.

Is magnesium orotate worth the higher cost?

On the published evidence, probably not. The cardiac research is small, unreplicated and done in diagnosed patients already on medication; the one trial in healthy athletes did not show a change in competitive performance; and orotic acid carries an unresolved safety question that EFSA could not close in 2025. For raising magnesium intake, cheaper forms such as glycinate or citrate deliver far more magnesium per capsule.

What is the recommended dosage of Magnesium Orotate?

The clinically studied dose is 6,000 mg/day for 1 month then 3,000 mg/day in the severe heart failure trial; 3,000 mg/day in the coronary heart disease pilot; 17 mmol/day (about 6,300 mg) for 4 weeks in the triathlete trial. Always follow the product label and check with a healthcare provider for personal advice.

Is Magnesium Orotate safe, and does it have side effects?

For most healthy adults, Magnesium Orotate is well tolerated at studied doses. Reported effects can include: Loose stools or diarrhea can occur, especially at higher doses, as with most magnesium salts. Mild stomach upset, nausea or abdominal cramping is possible in sensitive individuals. It may also interact with some medications. Magnesium Orotate is not right for everyone, so check with a healthcare provider first if you are pregnant or breastfeeding, have a medical condition, or take prescription medication.

Does Magnesium Orotate interact with any medications?

Possible interactions include: May reduce absorption of oral tetracycline and quinolone antibiotics; separate dosing by 2-4 hours. Can decrease absorption of oral bisphosphonates used for bone health; take several hours apart. If you take prescription medication, check with a pharmacist or doctor before using it.

How strong is the scientific evidence for Magnesium Orotate?

NutraSmarts rates the evidence for Magnesium Orotate as Limited (2 out of 5). It is backed by 2 clinical trials and 6 cited references summarized on this page. A higher rating reflects more, larger, and better-designed human studies.

References(6 citations)

Evidence ratings on NutraSmarts are based on the totality of human clinical research, with emphasis on randomized controlled trials, meta-analyses, and systematic reviews. The references below directly support claims made throughout this page.

  1. Stepura OB, Martynow AI Magnesium orotate in severe congestive heart failure (MACH) International Journal of Cardiology. 2009;Int J Cardiol. 2009 May 1;134(1):145-7.PubMedUsed to support: Monocentric double-blind randomized trial in 79 patients with NYHA class IV congestive heart failure on optimal medical therapy (40 magnesium orotate 6,000 mg/day for 1 month then 3,000 mg/day for about 11 months, 39 placebo). One-year survival was 75.7 percent versus 51.6 percent (p less than 0.05) and symptoms improved in 38.5 percent versus deteriorating in 56.3 percent on placebo (p less than 0.001). Published as a letter and corrected and republished in the same journal; no independent replication.
  2. Ranade VV, Somberg JC Bioavailability and pharmacokinetics of magnesium after administration of magnesium salts to humans American Journal of Therapeutics. 2001;Am J Ther. 2001 Sep-Oct;8(5):345-57.PubMedUsed to support: Narrative review of the bioavailability and pharmacokinetics of magnesium salts in humans. It examines how the anion paired with magnesium affects how much elemental magnesium reaches the target site, naming ionic magnesium, citrate, salicylate, hydroxide, mandelate, oxide, chloride, gluconate and lactate. It is a review rather than a trial, and magnesium orotate is not among the salts its abstract lists.
  3. Jahnen-Dechent W, Ketteler M Magnesium basics Clinical Kidney Journal. 2012;Clin Kidney J. 2012 Feb;5(Suppl 1):i3-i14.PubMedUsed to support: Review of magnesium physiology in general: dietary sources, intestinal absorption and renal handling, its role as an enzyme cofactor and as a natural calcium antagonist, and the consequences of hypomagnesaemia and hypermagnesaemia. It contains no data on magnesium orotate.
  4. EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA); Turck D, Bohn T, Cámara Hurtado MM, Castenmiller J, De Henauw S, et al. Safety of magnesium orotate dihydrate as a novel food pursuant to Regulation (EU) 2015/2283 and bioavailability of magnesium from this source in the context of Directive 2002/46/EC EFSA Journal. 2025;EFSA J. 2025 Jul 10;23(7):e9528.PubMedUsed to support: EFSA concluded that the safety of magnesium orotate dihydrate as a food supplement ingredient cannot be established at the proposed maximum intake of 6,100 mg/day, which supplies about 5,000 mg of orotic acid and 400 mg of magnesium. Several animal studies show tumour-promoting effects of orotic acid; the derived no-observed-adverse-effect level is 50 mg/kg body weight per day and the margin of exposure at the proposed use level is 0.7, lower than a margin the panel had already judged inadequate. The proposed magnesium intake also exceeds the EU upper limit of 250 mg/day for supplemental magnesium, and the assessment of magnesium bioavailability from this source compared with natural sources was not conducted.
  5. Golf SW, Bender S, Grüttner J On the significance of magnesium in extreme physical stress Cardiovascular Drugs and Therapy. 1998;Cardiovasc Drugs Ther. 1998 Sep;12 Suppl 2:197-202.PubMedUsed to support: Double-blind randomized study in 23 competitive triathletes given 17 mmol/day of magnesium orotate or placebo for 4 weeks before a 500 m swim, 20 km cycle and 5 km run. The supplemented group showed lower serum cortisol, a smaller rise in leukocytes and a smaller rise in creatine kinase (122 percent versus 140 percent), and swim, cycle and run times were lower than in the controls, but the authors concluded that the changes indicate a reduced stress response without affecting competitive potential. Published in a Cardiovascular Drugs and Therapy supplement issue devoted to orotic acid and magnesium orotate.
  6. Geiss KR, Stergiou N, Jester, Neuenfeld HU, Jester HG Effects of magnesium orotate on exercise tolerance in patients with coronary heart disease Cardiovascular Drugs and Therapy. 1998;Cardiovasc Drugs Ther. 1998 Sep;12 Suppl 2:153-6.PubMedUsed to support: Four-week double-blind pilot study in 14 patients with coronary heart disease and left ventricular dysfunction taking magnesium orotate 3 x 1 g per day on top of existing medication. Exercise duration increased (p = 0.011), left ventricular end-systolic volume fell (p = 0.016) and ejection fraction rose (p = 0.035). With 14 patients, a cardiac-rehabilitation population and no follow-up study, this is a preliminary result and not evidence for healthy people or for sports performance.